» Authors » Kate L Mahon

Kate L Mahon

Explore the profile of Kate L Mahon including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 23
Citations 419
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Yeung N, Li T, Lin H, Timmins H, Goldstein D, Harrison M, et al.
JCO Precis Oncol . 2024 May; 8:e2300690. PMID: 38691814
Purpose: Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting side effect of cytotoxic cancer treatment, often necessitating dose reduction (DR) or chemotherapy discontinuation (CD). Studies on peripheral neuropathy related to chemotherapy,...
2.
Mahon K, Sutherland S, Lin H, Stockler M, Gurney H, Mallesara G, et al.
Prostate . 2024 Mar; 84(8):747-755. PMID: 38544345
Background: Elevated circulating growth differentiation factor (GDF15/MIC-1), interleukin 4 (IL4), and IL6 levels were associated with resistance to docetaxel in an exploratory cohort of men with metastatic castration-resistant prostate cancer...
3.
Mak B, Lin H, Duong T, Mahon K, Joshua A, Stockler M, et al.
Cancers (Basel) . 2022 Oct; 14(19). PMID: 36230715
Elevated circulating sphingolipids are associated with shorter overall survival and therapeutic resistance in metastatic castration-resistant prostate cancer (mCRPC), suggesting that perturbations in sphingolipid metabolism promotes prostate cancer growth. This study...
4.
Conduit C, Mak B, Qu W, Lulio J, Burder R, Bressel M, et al.
Ther Adv Med Oncol . 2022 Apr; 14:17588359221092486. PMID: 35465297
Objective: To determine the efficacy and safety of intermittent docetaxel chemotherapy guided by circulating methylated glutathione S-transferase Pi-1 () in men with metastatic castration-resistant prostate cancer (CRPC). Patients And Methods:...
5.
Lin H, Mak B, Yeung N, Huynh K, Meikle T, Mellett N, et al.
EBioMedicine . 2021 Oct; 72:103625. PMID: 34656931
Background: Intrinsic resistance to androgen receptor signalling inhibitors (ARSI) occurs in 20-30% of men with metastatic castration-resistant prostate cancer (mCRPC). Ceramide metabolism may have a role in ARSI resistance. Our...
6.
Lin H, Yeung N, Hastings J, Croucher D, Huynh K, Meikle T, et al.
Cancers (Basel) . 2021 Oct; 13(19). PMID: 34638448
Circulating lipids or cytokines are associated with prognosis in metastatic castration-resistant prostate cancer (mCRPC). This study aimed to understand the interactions between lipid metabolism and immune response in mCRPC by...
7.
Lin H, Huynh K, Kohli M, Tan W, Azad A, Yeung N, et al.
Prostate Cancer Prostatic Dis . 2021 Mar; 24(3):860-870. PMID: 33746214
Background: Dysregulated lipid metabolism is associated with more aggressive pathology and poorer prognosis in prostate cancer (PC). The primary aim of the study is to assess the relationship between the...
8.
Nindra U, Shahnam A, Mahon K
Asia Pac J Clin Oncol . 2021 Feb; 18(1):7-12. PMID: 33609014
Colorectal cancer remains the third most common malignancy in Australia with the peritoneum being the second most common metastatic site. Colorectal peritoneal carcinomatosis (CPC) can be treated with cytoreductive surgery...
9.
Scheinberg T, Goodwin A, Ip E, Linton A, Mak B, Smith D, et al.
JCO Oncol Pract . 2020 Sep; 17(2):e204-e216. PMID: 32970524
Purpose: To identify the approximately 12% with inherited cancer predisposition, all men with metastatic prostate cancer (mPC) should be offered germline genetic testing. This guides treatment choices and impacts cancer...
10.
Miladinovic D, Cusick T, Mahon K, Haynes A, Cortie C, Meyer B, et al.
Cancers (Basel) . 2020 Jun; 12(6). PMID: 32481537
The prostate is surrounded by periprostatic adipose tissue (PPAT), the thickness of which has been associated with more aggressive prostate cancer (PCa). There are limited data regarding the functional characteristics...